ORAMED PHARMACEUTICALS INC (ORMP) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ORMP • US68403P2039

3.41 USD
+0.17 (+5.25%)
At close: Feb 6, 2026
3.4 USD
-0.01 (-0.29%)
After Hours: 2/6/2026, 4:30:02 PM
Fundamental Rating

5

ORMP gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. While ORMP has a great health rating, there are worries on its profitability. ORMP has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year ORMP was profitable.
  • In the past year ORMP has reported a negative cash flow from operations.
  • In the past 5 years ORMP reported 4 times negative net income.
  • In the past 5 years ORMP always reported negative operating cash flow.
ORMP Yearly Net Income VS EBIT VS OCF VS FCFORMP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 19.89%, ORMP belongs to the top of the industry, outperforming 97.38% of the companies in the same industry.
  • The Return On Equity of ORMP (21.57%) is better than 91.62% of its industry peers.
Industry RankSector Rank
ROA 19.89%
ROE 21.57%
ROIC N/A
ROA(3y)-10.8%
ROA(5y)-15.12%
ROE(3y)-11.25%
ROE(5y)-17.59%
ROIC(3y)N/A
ROIC(5y)N/A
ORMP Yearly ROA, ROE, ROICORMP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

  • The Profit Margin of ORMP (2192.60%) is better than 99.48% of its industry peers.
  • The Operating Margin and Gross Margin are not available for ORMP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 2192.6%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ORMP Yearly Profit, Operating, Gross MarginsORMP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • ORMP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ORMP has less shares outstanding
  • The number of shares outstanding for ORMP has been increased compared to 5 years ago.
  • ORMP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ORMP Yearly Shares OutstandingORMP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ORMP Yearly Total Debt VS Total AssetsORMP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 4.24 indicates that ORMP is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of ORMP (4.24) is better than 70.68% of its industry peers.
  • There is no outstanding debt for ORMP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.24
ROIC/WACCN/A
WACC8.89%
ORMP Yearly LT Debt VS Equity VS FCFORMP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • ORMP has a Current Ratio of 22.24. This indicates that ORMP is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 22.24, ORMP belongs to the top of the industry, outperforming 91.62% of the companies in the same industry.
  • A Quick Ratio of 22.24 indicates that ORMP has no problem at all paying its short term obligations.
  • ORMP has a Quick ratio of 22.24. This is amongst the best in the industry. ORMP outperforms 92.15% of its industry peers.
Industry RankSector Rank
Current Ratio 22.24
Quick Ratio 22.24
ORMP Yearly Current Assets VS Current LiabilitesORMP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • ORMP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 726.67%, which is quite impressive.
  • The Revenue for ORMP has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)726.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, ORMP will show a very negative growth in Earnings Per Share. The EPS will decrease by -30.19% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y825.33%
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%
EPS Next 5Y-30.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ORMP Yearly Revenue VS EstimatesORMP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2025 500K 1M 1.5M 2M 2.5M
ORMP Yearly EPS VS EstimatesORMP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 -1

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 2.75, which indicates a rather cheap valuation of ORMP.
  • ORMP's Price/Earnings ratio is rather cheap when compared to the industry. ORMP is cheaper than 97.38% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of ORMP to the average of the S&P500 Index (27.92), we can say ORMP is valued rather cheaply.
  • ORMP is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 2.75
Fwd PE N/A
ORMP Price Earnings VS Forward Price EarningsORMP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ORMP Per share dataORMP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • ORMP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A cheap valuation may be justified as ORMP's earnings are expected to decrease with -66.87% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 7.42%, ORMP is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.61, ORMP pays a better dividend. On top of this ORMP pays more dividend than 98.43% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.83, ORMP pays a better dividend.
Industry RankSector Rank
Dividend Yield 7.42%

5.2 History

  • ORMP does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
ORMP Yearly Dividends per shareORMP Yearly Dividends per shareYearly Dividends per share 2026 0.05 0.1 0.15 0.2

5.3 Sustainability

DPN/A
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%
ORMP Yearly Income VS Free CF VS DividendORMP Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

More info and screens

Find the best dividend stocksShow peers with best dividend

ORAMED PHARMACEUTICALS INC

NASDAQ:ORMP (2/6/2026, 4:30:02 PM)

After market: 3.4 -0.01 (-0.29%)

3.41

+0.17 (+5.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-08
Earnings (Next)03-25
Inst Owners18.24%
Inst Owner Change27.32%
Ins Owners12.73%
Ins Owner Change15.95%
Market Cap135.72M
Revenue(TTM)2.00M
Net Income(TTM)43.85M
Analysts43.33
Price Target3.32 (-2.64%)
Short Float %1.21%
Short Ratio1.62
Dividend
Industry RankSector Rank
Dividend Yield 7.42%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date01-16
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1852.45%
Min EPS beat(2)859.8%
Max EPS beat(2)2845.1%
EPS beat(4)3
Avg EPS beat(4)510.54%
Min EPS beat(4)-1762.75%
Max EPS beat(4)2845.1%
EPS beat(8)6
Avg EPS beat(8)-569.36%
EPS beat(12)10
Avg EPS beat(12)-366.78%
EPS beat(16)11
Avg EPS beat(16)-276.91%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)100%
EPS NY rev (1m)0%
EPS NY rev (3m)476.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 2.75
Fwd PE N/A
P/S 67.86
P/FCF N/A
P/OCF N/A
P/B 0.67
P/tB 0.67
EV/EBITDA N/A
EPS(TTM)1.24
EY36.36%
EPS(NY)-1.29
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS0.05
BVpS5.11
TBVpS5.11
PEG (NY)0
PEG (5Y)N/A
Graham Number11.94
Profitability
Industry RankSector Rank
ROA 19.89%
ROE 21.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 2192.6%
GM N/A
FCFM N/A
ROA(3y)-10.8%
ROA(5y)-15.12%
ROE(3y)-11.25%
ROE(5y)-17.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 14.75%
Cap/Sales 0.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.24
Quick Ratio 22.24
Altman-Z 4.24
F-Score5
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)324.08%
Cap/Depr(5y)449.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)726.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%333.33%
EPS Next Y825.33%
EPS Next 2Y-167.21%
EPS Next 3Y-66.87%
EPS Next 5Y-30.19%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.49%
OCF growth 3YN/A
OCF growth 5YN/A

ORAMED PHARMACEUTICALS INC / ORMP FAQ

What is the fundamental rating for ORMP stock?

ChartMill assigns a fundamental rating of 5 / 10 to ORMP.


What is the valuation status for ORMP stock?

ChartMill assigns a valuation rating of 4 / 10 to ORAMED PHARMACEUTICALS INC (ORMP). This can be considered as Fairly Valued.


How profitable is ORAMED PHARMACEUTICALS INC (ORMP) stock?

ORAMED PHARMACEUTICALS INC (ORMP) has a profitability rating of 3 / 10.


What are the PE and PB ratios of ORAMED PHARMACEUTICALS INC (ORMP) stock?

The Price/Earnings (PE) ratio for ORAMED PHARMACEUTICALS INC (ORMP) is 2.75 and the Price/Book (PB) ratio is 0.67.


How financially healthy is ORAMED PHARMACEUTICALS INC?

The financial health rating of ORAMED PHARMACEUTICALS INC (ORMP) is 9 / 10.